Zobrazeno 1 - 10
of 489
pro vyhledávání: '"Ehringer, H."'
Autor:
T. Endler, F. Gabl, M. Hirschl, Ehringer H, H. Ingerle, U. Konecny, E. Deutsch, L Marosi, Erich Minar
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 105:1713-1717
GOT, GPT and some other enzyme levels were measured systematically in 46 patients receiving subcutaneous heparin treatment. The heparin dosage varied between 5,000 and 15,000 IU, given every eight hours. During heparinisation a rise in GPT (average m
Autor:
Ehringer H, Ch. Pollak, M. Hirschl, L Marosi, G. Sommer, Czembirek H, Erich Minar, U. Konecny
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 107:1303-1309
Among 279 consecutive patients (average age 53.8 years) with acute venous thrombosis, "complete" or "nearly complete" search for neoplasm was undertaken in 93 (average 60.6 years), "not complete" search in 186 (average 50.1 years). Subsequently the p
Autor:
Ehringer H, Marosi L
Publikováno v:
Ultraschall in der Medizin. 5:174-181
Using a high-resolution ultrasound real time scanner the average normal appearance of the carotid bifurcation, variations and especially norms for the average diameters of the common, internal and external carotid arteries were established in 53 heal
Autor:
G. Schnürer, Michael E. Gschwandtner, Erich Minar, Willfort A, A. Ahmadi, Ehringer H, M. Haumer, Peter Polterauer, Meissl G, Hülsmann M, T. Maca
Publikováno v:
Vasa. 28:271-278
Background: Different therapies in consecutive patients (1987–1992) with chronic critical limb ischemia at a department of medical angiology, their short- and long-term outcome were investigated. Patients and methods: 190 patients (112 males, 78 fe
Publikováno v:
Thrombosis and Haemostasis. 81:498-501
Summary Background: Direct thrombin inhibitors belong to a new class of antithrombotic drugs whose effects on blood coagulation in vivo in patients suffering from acute thrombotic conditions have not yet been fully explored. Methods and Results: One
Publikováno v:
Thrombosis and Haemostasis. 78:0997-1002
SummaryOne hundred and ten patients with acute proximal deep-vein thrombosis were randomized in a sequential dose-finding design, to receive continuous intravenous infusion of napsagatran, a novel synthetic thrombin-inhibitor, at a fixed dose of 5 mg